Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-label, Single Intravenous Infusion Dose Study to Evaluate the Mass Balance, Pharmacokinetics, Metabolism, and Excretion of TAK-954 Containing Microtracer ([14C]-TAK-954) in Healthy Adult Male Subjects

Trial Profile

A Phase 1, Open-label, Single Intravenous Infusion Dose Study to Evaluate the Mass Balance, Pharmacokinetics, Metabolism, and Excretion of TAK-954 Containing Microtracer ([14C]-TAK-954) in Healthy Adult Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Jul 2018

At a glance

  • Drugs TD 8954 (Primary)
  • Indications Diabetic gastroparesis; Gastrointestinal motility disorders
  • Focus Pharmacokinetics
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 02 Jul 2018 Status changed from recruiting to completed.
    • 18 May 2018 Status changed from not yet recruiting to recruiting.
    • 20 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top